modelA02BC54
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | RabeprazoleCombinations | |
| ATC code: | A02BC54 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 29.6 | L |
| clearance: | 283 | mL/min |
| other parameters in model implementation | ||
Rabeprazole is a proton pump inhibitor (PPI) used to reduce gastric acid production. It is commonly indicated in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and conditions involving excessive gastric acid secretion. The 'combinations' formulation may include other agents for synergistic effect on gastric acid suppression. Rabeprazole is currently approved and widely used in clinical practice.
Pharmacokinetics
No published compartmental pharmacokinetic models specifically available for rabeprazole combination products (A02BC54); parameters herein are estimated based on known data for monotherapy in healthy adults.
References
Litalien, C, et al., & Faure, C (2005). Pharmacokinetics of proton pump inhibitors in children. Clinical pharmacokinetics 44(5) 441–466. DOI:10.2165/00003088-200544050-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15871633
Lu, T, et al., & Ware, JA (2017). Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics. CPT: pharmacometrics & systems pharmacology 6(11) 747–755. DOI:10.1002/psp4.12228 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28748626
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)